Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis

Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571–84.

Article  PubMed  Google Scholar 

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384–413.

Article  PubMed  Google Scholar 

Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment. J Crohns Colitis. 2022;16:2–17.

Article  PubMed  Google Scholar 

Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489–526.

Article  PubMed  PubMed Central  Google Scholar 

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

Article  CAS  PubMed  Google Scholar 

Sandborn WJ, Van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65.e1.

Article  CAS  PubMed  Google Scholar 

Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95 quiz e14.

Article  CAS  PubMed  Google Scholar 

Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.e1.

Article  CAS  PubMed  Google Scholar 

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.

Article  CAS  PubMed  Google Scholar 

Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–14.

Article  CAS  PubMed  Google Scholar 

Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: Evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182–97.

Article  PubMed  Google Scholar 

Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1353–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, et al. Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension. J Crohns Colitis. 2022;16:1222–34.

Article  PubMed  PubMed Central  Google Scholar 

Papamichael K, Rivals-Lerebours O, Billiet T, VandeCasteele N, Gils A, Ferrante M, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohns Colitis. 2016;10:1015–23.

Article  PubMed  Google Scholar 

Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3.

Article  CAS  PubMed  Google Scholar 

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.

Article  CAS  PubMed  Google Scholar 

Qiu Y, Mao R, Zhang S-H, Li M-Y, Guo J, Chen B-L, et al. Safety profile of thiopurines in Crohn disease: Analysis of 893 patient-years follow-up in a Southern China cohort. Medicine (Baltimore). 2015;94:e1513.

Article  CAS  PubMed  Google Scholar 

Yang S-K, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46:1017–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53:1065–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin Gastroenterol Hepatol. 2021;19:1366-1376.e2.

Article  CAS  PubMed  Google Scholar 

Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15:229-239.e5.

Article  CAS  PubMed  Google Scholar 

Singh S, George J, Boland BS, VandeCasteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: A systematic review and meta-analysis. J Crohns Colitis. 2018;12:635–43.

Article  PubMed  PubMed Central  Google Scholar 

Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut. 2019;68:814–28.

Article  CAS  PubMed  Google Scholar 

Gazouli M, Dovrolis N, Bourdakou MM, Gizis M, Kokkotis G, Kolios G, et al. Response to anti-α4β7 blockade in patients with ulcerative colitis is associated with distinct mucosal gene expression profiles at baseline. Inflamm Bowel Dis. 2022;28:87–95.

Article  PubMed  Google Scholar 

Alric H, Amiot A, Kirchgesner J, Tréton X, Allez M, Bouhnik Y, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51:948–57.

Article  CAS  PubMed  Google Scholar 

Biemans VB, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Löwenberg M, de Boer NK, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52:123–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif